Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: Results from the German competence network CAPNETZ

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Zobel, Katrin ^a   Martus, Peter ^b   Pletz, Mathias W ^c   Ewig, Santiago ^d   Prediger, Michael ^a   Welte, Tobias ^e   Bühling, Frank ^a,e  

^a CARL THIEM KLINIKUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d Respiratory and Infectious Diseases   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Biomarker; CAP; Cytokine; Interleukin 10; Interleukin 6; LBP; Pneumonia

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CARRIER PROTEIN; CYTOKINE; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

ACCURACY; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BLOOD SAMPLING; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CRB 65 SCORE; DEATH; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SPUTUM; STREPTOCOCCUS PNEUMONIAE; URINE; VIRUS INFECTION; ADOLESCENT; BLOOD; COMMUNICABLE DISEASE; HOSPITALIZATION; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA; RISK FACTOR; VIROLOGY;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARRIER PROTEINS; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PNEUMONIA; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84857131570     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-6     Document Type: Article

References (37)

1. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004, 32:234-238.
2. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000, 15:757-763. 10.1034/j.1399-3003.2000.15d21.x, 10780770.
3. Ewig S, Torres A, Woodhead M. Assessment of pneumonia severity: a European perspective. Eur Respir J 2006, 27:6-8. 10.1183/09031936.06.00130205, 16387928.
4. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006, 260:93-101. 10.1111/j.1365-2796.2006.01657.x, 16789984.
5. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20. 10.1042/BJ20030407, 1223585, 12773095.
6. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005, 77:3-15.
7. Schumann RR, Zweigner J. A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med 1999, 37:271-274. 10.1515/CCLM.1999.047, 10353471.
8. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005, 175:3463-3468.
9. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance?. Exerc Immunol Rev 2006, 12:6-33.
10. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008, 31:349-355. 10.1183/09031936.00054507, 17959641.
11. Kruger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, Suttor N, Welte T. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009, 10:65. 10.1186/1465-9921-10-65, 2714042, 19594893.
12. Infektionen der tiefen Atemwege Quality standards for microbiological diagnostic techniques for infectious diseases 2000, 2011. Munich: Urban & Fischer Verlag, Mauch H, Lütticken R, Gatermann S, Infektionen der tiefen Atemwege.
13. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. 10.1002/sim.2929, 17569110.
14. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21. 10.1002/sim.4085, 21204120.
15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845. 10.2307/2531595, 3203132.
16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250. 10.1056/NEJM199701233360402, 8995086.
17. Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, Bilbao A. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006, 27:151-157. 10.1183/09031936.06.00062505, 16387948.
18. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006, 61:419-424. 10.1136/thx.2005.051326, 2111174, 16449258.
19. Kruger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 2010, 65:208-214. 10.1136/thx.2009.121178, 20335288.
20. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010, 182:1426-1434. 10.1164/rccm.201003-0415OC, 20639437.
21. Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994, 150:710-716.
22. Kolsuz M, Erginel S, Alatas O, Alatas F, Metintas M, Ucgun I, Harmanci E, Colak O. Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia. Respiration 2003, 70:615-622. 10.1159/000075208, 14732793.
23. Wu CL, Chan MC, Chang GC, Lee YL, Chin CS, Chang KM, Hsu JY. Etiology and cytokine expression in patients requiring mechanical ventilation due to severe community-acquired pneumonia. J Formos Med Assoc 2006, 105:49-55. 10.1016/S0929-6646(09)60108-X, 16440070.
24. Fernandez-Serrano S, Dorca J, Coromines M, Carratala J, Gudiol F, Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003, 10:813-820. 193876, 12965910.
25. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999, 180:1584-1589. 10.1086/315093, 10515819.
26. Blairon L, Wittebole X, Laterre PF. Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis 2003, 187:287-291. 10.1086/346046, 12552453.
27. Masia M, Gutierrez F, Padilla S, Soldan B, Mirete C, Shum C, Hernandez I, Royo G, Martin-Hidalgo A. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 2007, 13:153-161.
28. Tejera A, Santolaria F, Diez ML, Aleman-Valls MR, Gonzalez-Reimers E, Martinez-Riera A, Milena-Abril A. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 2007, 38:117-123. 10.1016/j.cyto.2007.05.002, 17659879.
29. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355:2615-2617. 10.1056/NEJMp068249, 17182986.
30. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007, 167:1655-1663. 10.1001/archinte.167.15.1655, 17698689.
31. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999, 27:1262-1264. 10.1097/00003246-199907000-00005, 10446817.
32. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004, 11:161-167. 321326, 14715564.
33. Ewig S, Torres A, Angeles MM, Angrill J, Rano A, de Roux A, Mensa J, Martinez JA, de la Bellacasa JP, Bauer T. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002, 20:1254-1262. 10.1183/09031936.02.01942001, 12449182.
34. Schultz MJ. Cytokines and host defense in pneumonia. Intensivmedizin und Notfallmedizin, Band 36, Heft 3 1999, Darmstadt: Steinkopff-Verlag.
35. Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008, 63:447-452. 10.1136/thx.2007.086785, 18245147.
36. Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest 2007, 132:1348-1355. 10.1378/chest.06-1995, 17934120.
37. Masia M, Gutierrez F, Llorca B, Navarro JC, Mirete C, Padilla S, Hernandez I, Flores E. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004, 50:1661-1664. 10.1373/clinchem.2004.031294, 15331500.